01 May 2011: Clinical Research
Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients
Elif Sahin Horasan ABCDEF , Gulden Ersoz BCDE , Anil Tombak BD , Naci Tiftik BD , Ali Kaya BDE
DOI: 10.12659/MSM.881773
Med Sci Monit 2011; 17(5): CR304-309
Background
Chemotherapy-induced neutropenia is a major adverse effect of cancer treatment. Bacteremia (BSI) was documented in blood cultures (BC) in 11–30% of the febrile neutropenia (FN) episodes [1–5]. The mortality from FN may be as high as 10%, depending on the population studied, and FN is still responsible for the majority of chemotherapy-associated deaths [6–8]. It includes a spectrum of clinical syndromes ranging from non-infectious fever to severe life-threatening infections. Patients with FN and bacteremia form a small subgroup within this spectrum, including severely infected patients. The epidemiology of bacteremic febrile neutropenia constitutes the basis for selection of empiric antibiotic therapy for febrile neutropenia [9]. There has been a shift from the predominance of gram-negative bacteria to predominance of gram-positive bacteria in many centers over the past 2 decades [10–13]; however, in recent years there has been a reverse of this trend in several centers. In fact, these centers reported the re-emergence of gram-negative bacteria in febrile neutropenic patients [14,15]. The significant variability between locations requires investigation of local trends to guide more appropriate antibiotic treatment.
Therefore, we performed a prospective cohort study to evaluate the causative bacteria and to identify risk factors for mortality in febrile neutropenic patients with BSI.
Material and Methods
STATISTICAL ANALYSIS:
The SPSS 11.5 (Chicago, IL) package program was used for statistical analysis. Univariate statistical analysis including Student’s t test was used for continuous data. Chi-square and Fisher’s exact test were used for categorical data. P values of <0.05 were considered significant. Multivariate logistic regression analysis was performed to determine risk factors independently associated with mortality.
Results
Throughout the study period, the patients developed 420 febrile neutropenic episodes. Out of 420 episodes, only 90 (21.4%) were found to have BSI. The mean age of the patients was 45.6±18.4 years and 55.6% of the patients were male. The median time to development of BSI was 9.4±10.7 days (range 1–63). A total of 98 isolates were recovered from the cases of BSI. Polymicrobial bacteremia was detected in 6 episodes (6.7%). Forty-nine patients (54.4%) were in the low-risk group, 78 (86.7%) had hematogenous malignity, and 12 patients (13.3%) had solid malignancies. Thirty patients died. Of total bloodstream infections, 59.1% were nosocomial, and the most frequent underlying type of malignancy was AML (n=41). Table 1 shows the distribution of the patients by their diagnoses.
Gram-positive bacteria were more frequently isolated than gram-negative bacteria throughout the study period. Table 2 shows the distribution of causative bacteria. Coagulase-negative
Univariate analyses (Table 3) showed a significant relation between mortality and MASSC scores (p=0.000) and several characteristics of causative agents. The relation between mortality and gram-negative bacteria, acinetobacteria, nonfermentative bacteria, stay in intensive care unit (ICU) wards and coagulase-negative staphylococci (CoNS) was significant (p=0.002, 0.005, 0.009,0.002,0.0001, 0.0001, respectively).
Multivariate analyses showed that MASSC scores (p=0.0001, OR=15.1, CI%95 4.5–50.7), stay in ICU wards (p=0.0002, OR= 8.6, Cl%95 1.101–68,157) and CoNS were independent risk factors associated with mortality (p=0.004, OR=12.12, CI%95 2.3–64.7) (Table 3). BSI due to CoNS was associated with lower mortality; however, MASCC high risk score and ICU stay were associated with higher mortality.
Discussion
Our study found that 21.4% of the febrile neutropenic patients with cancer had BSI. This is consistent with other reports showing that up to 30% of the episodes of FN are associated with confirmed bacteremia [5,6–18]. The most commonly isolated bacteria in the present series were CoNS, which accounted for 33 of 98 (33.7%) blood culture isolates, similar to other studies [5,19].
Overall, gram-positive organisms accounted for nearly 50% (n=47, 47.9%) of all blood culture isolates. These data support the documented high rates of gram-positive infections in cancer patients with FN [6–19]. In fact, prior studies revealed that 50%–71% of the etiological agents found in microbiological analyses in FN patients with BSI were gram-positive bacteria [5,21,22,23]; however, the rate of gram-negative infections is on the rise in some centers [24,25,26]. Recently, non-fermentative gram-negative rods such as
Although the most frequent causative agents were gram-positive bacteria throughout the study period, there was a significant increase in gram-negative bacteria, especially acinetobacteria, in the last 2 years of the study; 30.7% and 62.8% of the isolates had gram-negative bacteria in the first and the last 2 years of the study, respectively. Recently, Chen et al reported that gram-negative bacteria were the predominant pathogens (60%) and that fungi were relatively uncommon (6%) in bloodstream infections in patients with neutropenia. In addition, the number of Acinetobacter and Stenotrophomonas infections increased from 2002 to 2006, and were the third (7%) and fourth (6%) most frequent after
Our multivariate analysis revealed that isolation of a CoNs strain and MASSC index-score are independent predictors of mortality in patients with FN and BSI. Uys et al showed that the MASCC risk-index score correctly identifies low- and high-risk patients at presentation with febrile neutropenia [30]. This study showed that the MASCC risk-index score had a positive predictive value of 98.3% and a negative predictive value of 86.4%, with both a sensitivity and specificity of 95%.
We found that mortality was 10.2% in the low-risk patients with the MASSC score of 21 and above and 60.8% in the high-risk patients (p=0.000). Consistent with the results of the present study, Klastersky et al. [22] reported a relatively low rate of overall complications (18%) and death (3%) in low-risk patients with bacteremia and MASCC scores of >21, but that when the MASCC score was <21, the corresponding figures were 49% and 19% (
Prior studies have revealed that gram-negative bacteremia is usually associated with higher case fatality rates than gram-positive infections, and that the risk is further increased due to antimicrobial resistance if effective treatment is delayed [23,31–34].
In the present study, 43.2% of gram-negative bacteria were multi-drug resistant, and 20.5% of these bacteria were highly resistant bacteria such as acinetobacteria. This might have contributed to the increase in the mortality due to gram-negative bacteria. In addition, gram-positive bacteria are isolated easily and quickly; therefore, they are easily identified, which allows treatment. This may explain the low mortality from gram-positive bacteria.
Conclusions
There has been an increase in the rate of bloodstream infections due to antimicrobial-resistant gram-negative bacteria in FN patients. Bacterial epidemiology and antimicrobial resistance in these patients should be regularly monitored, which will provide guidance for local policies for the use of antimicrobial agents and the assist in the choice of agents for empirical antibiotic therapy and prophylaxis in FN patients. The MASCC risk-index score and emerging of CoNS in positive blood cultures are valuable tools in the management of patients with febrile neutropenia, and can be used to accurately predict mortality in patients with BSI.
References
1. Petrilli AS, Melaragno R, Barros KV, Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease: Pediatr Infect Dis J, 1993; 12(11); 916-21, pmid: 8265281
2. Oude Nijhuis C, Kamps WA, Daenen SM, Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients: J Clin Oncol, 2005; 23(30); 7437-44, pmid: 16234511
3. Hodgson-Viden H, Grundy PE, Robinson JL, Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia: BMC Pediatr, 2005; 5(1); 10, pmid: 15904510
4. Santolaya ME, Villarroel M, Avendano LF, Cofre J, Discontinuation of antimicrobial therapy for febrile neutropenic children with cancer: a prospective study: Clin Infect Dis, 1997; 25(1); 92-97, pmid: 9243041
5. Morris PG, Hassan T, McNamara M, Emergence of MRSA in positive blood cultures from patients with febrile neutropenia a cause for concern: Support Care Cancer, 2008; 16(9); 1085-88, pmid: 18274787
6. Sipsas NV, Bodey GP, Kontoyiannis DP: Cancer, 2005; 103; 1103-13, pmid: 15666328
7. Smith PF, Birmingham MC, Noskin GA, Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia: Ann Oncol, 2003; 14; 795-801, pmid: 12702536
8. Elting LS, Rubenstein EB, Rolston K, Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care: J Clin Oncol, 2000; 18; 3699-706, pmid: 11054443
9. Paul M, Gafter-Gvili A, Leibovici L, The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988–2004: Isr Med Assoc J, 2007; 9(6); 424-29, pmid: 17642387
10. Viscoli C, Varnier O, Machetti M, Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification: Clin Infect Dis, 2005; 40(Suppl 4); S240-45, pmid: 15768329
11. Ramphal R, Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens: Clin Infect Dis, 2004; 39(Suppl 1); S25-31, pmid: 15250017
12. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB, Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States: Clin Infect Dis, 2003; 36; 1103-10, pmid: 12715303
13. Zinner SH, Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria: Clin Infect Dis, 1999; 29; 490-94, pmid: 10530434
14. Haupt R, Romanengo M, Fears T, Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: a 12-year experience at a single Italian institution: Eur J Cancer, 2001; 37; 2413-19, pmid: 11720836
15. Wang FD, Lin ML, Liu CY, Bacteremia in patients with hematological malignancies: Chemotherapy, 2005; 51; 147-53, pmid: 15886475
16. Meunier F, Lukan C, The First European Conference on Infections in Leukaemia – ECIL1: a current perspective: Eur J Cancer, 2008; 44(15); 2112-17, pmid: 18707872
17. Klastersky J, Paesmans M, Rubenstein EB, The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients: J Clin Oncol, 2000; 18; 3038-51, pmid: 10944139
18. Rolston KV, Challenges in the treatment of infections caused by Gram-positive and Gram-negative bacteria in patients with cancer and neutropenia: Clin Infect Dis, 2005; 40; S246-52, pmid: 15768330
19. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Grañena A, Gudiol F, Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution: Eur J Clin Microbiol Infect Dis, 1996; 15; 291-96, pmid: 8781879
20. Wojak I, Gospodarek E, Analysis of microorganisms isolated from febrile neutropenic children with neoplastic disease: Med Dosw Mikrobiol, 2004; 56; 411-19, pmid: 15959998
21. Irfan S, Idrees F, Mehraj V, Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study: BMC Infect Dis, 2008; 8; 80, pmid: 18541017
22. Klastersky J, Ameye L, Maertens J, Bacteraemia in febrile neutropenic cancer patients: Int J Antimicrob Agents, 2007; 30(Suppl 1); S51-59, pmid: 17689933
23. Tumbarello M, Spanu T, Caira M, Factors associated with mortality in bacteremic patients with hematologic malignancies: Diagn Microbiol Infect Dis, 2009; 64(3); 320-26, pmid: 19345033
24. Chen CY, Tang JL, Hsueh PR, Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy: J Formos Med Assoc, 2004; 103; 526-32, pmid: 15318274
25. Guven GS, Uzun O, Cakir B, Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997–2001): Support Care Cancer, 2006; 14; 52-55, pmid: 15947955
26. Velasco E, Byington R, Martins CS, Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects: Clin Microbiol Infect, 2004; 10; 542-49, pmid: 15191383
27. Chen CY, Tsay W, Tang JL, Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia: Epidemiol Infect, 2009; 27; 1-8
28. Wisplinghoff H, Bischoff T, Tallent SM, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study: Clin Infect Dis, 2004; 39; 309-17, pmid: 15306996
29. Velasco E, Byington R, Martins CA, Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections: Eur J Clin Microbiol and Infect Dis, 2006; 25; 1-7, pmid: 16424972
30. Uys A, Rapoport BL, Anderson R, Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score: Support Care Cancer, 2004; 12; 555-60, pmid: 15197637
31. Anderson DJ, Engemann JJ, Harrell LJ: Antimicrob Agents Chemother, 2006; 50; 1715-20, pmid: 16641440
32. Blot S, Vandewoude K, De Bacquer D, Colardyn F, Nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization: Clin Infect Dis, 2002; 34; 1600-6, pmid: 12032895
33. Schwaber MJ, Carmeli Y: J Antimicrob Chemother, 2007; 60; 913-20, pmid: 17848376
34. Tumbarello M, Sanguinetti M, Montuori E: Antimicrob Agents Chemother, 2007; 51; 1987-94, pmid: 17387156
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






